

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claims 1-18 (Canceled).

19. (Previously Presented) A composition comprising a recovered population of peptides in admixture with a pharmaceutically acceptable non toxic carrier, wherein said recovered population of peptides is produced by a method comprising the steps of:

- (a) purifying a population of stress protein-peptide complexes from mammalian tumor cells, wherein the stress protein is non covalently associated with the peptide in said complexes;
- (b) releasing the peptides from said population of complexes to produce a released population of peptides; and
- (c) recovering the released population of peptides.

Claims 20-21 (Canceled).

22. (Previously Presented) The composition of claim 19 further comprising a cytokine.

23. (Previously Presented) The composition of claim 22 wherein said cytokine is selected from the group consisting of IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IFN α , IFN β , IFN γ , TNF α , TNF β , G-CSF, GM-CSF, and TGF- β .

24. (Currently Amended) The composition of claim 19 wherein the peptides are released from said population of complexes by a method comprising placing said population of complexes in the presence of adenosine triphosphate, ~~low pH, or both.~~

25. (Previously Presented) The composition of claim 19, wherein said mammalian tumor cells are human cells.

26. (Previously Presented) The composition of claim 19 wherein said mammalian tumor cells are from a tumor selected from the group consisting of melanocarcinoma, hepatocarcinoma, and renal cell carcinoma.

27. (Previously Presented) The composition of claim 19 wherein said tumor cells are from a metastasis.

28. (Previously Presented) The composition of claim 19, wherein said tumor cells have been proliferated in vivo.

29. (Previously Presented) The composition of claim 19, wherein said tumor cells have been proliferated in vitro.

30. (Previously Presented) The composition of claim 19, wherein the stress protein is a member of a stress protein family selected from the group consisting of hsp60, hsp70, and hsp90.

31. (Previously Presented) The composition of claim 19, wherein the stress protein is gp96.

Claims 32-51 (Canceled).

52. (Previously Presented) The composition of claim 19, wherein the stress protein is hsp70.

53. (Previously Presented) The composition of claim 19, which further comprises a pharmaceutically acceptable carrier.

54. (Previously Presented) The composition of claim 19, further comprising an adjuvant.

55. (Previously Presented) The composition of claim 19 wherein the adjuvant is selected from the group consisting of a pluronic tri-block copolymer, muramyl dipeptide, detoxified endotoxin, saponin, QS-21, and liposome.